Teva Pharma Industries Ltd ADR

Yahoo Finance • 7 days ago

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available... Full story

Yahoo Finance • 10 days ago

$198.39 Bn Active Pharmaceutical Ingredients (API) Markets, 2030 by Synthesis (synthetic, Biotech), Potency (HPAPI), Product (mAbs, Hormones), Drug (OTC, Rx), Application (Diabetes, Oncology)

Company Logo The global active pharmaceutical ingredients (API) market is poised to reach USD 198.39 billion by 2030, witnessing a CAGR of 6.6% from USD 144.20 billion in 2025. The API market's growth is significantly driven by expanding... Full story

Yahoo Finance • 10 days ago

Stanley Druckenmiller's Strategic Moves: A Closer Look at State Street Financial Select Sector ...

This article first appeared on GuruFocus. Insights from the Fourth Quarter 2025 13F Filing Stanley Druckenmiller (Trades, Portfolio) recently submitted his 13F filing for the fourth quarter of 2025, revealing strategic investment decisio... Full story

Yahoo Finance • 11 days ago

Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease

[Scientist analyzing red liquid or blood under a microscope] fotostorm/E+ via Getty Images * Teva Pharmaceutical (TEVA [https://seekingalpha.com/symbol/TEVA]) and Sanofi (SNY [https://seekingalpha.com/symbol/SNY]) on Tuesday reported th... Full story

Yahoo Finance • 11 days ago

Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an a... Full story

Yahoo Finance • 11 days ago

Communiqué de presse : Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn

Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn Dans l’étude de phase IIb RELIEVE UCCD LTE,... Full story

Yahoo Finance • 11 days ago

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the... Full story

Yahoo Finance • 16 days ago

Asthma Drugs Market to Reach USD 41.18 Billion by 2035 | Biologic Therapies Accelerate Shift Toward Targeted Treatment Says Astute Analytica

AstuteAnalytica India Pvt. Ltd. High-value biologic therapies are overtaking traditional treatments, driving revenue despite pricing pressures on standard inhalers. The market is bifurcating, with innovation focused on severe phenotypes a... Full story

Yahoo Finance • 24 days ago

Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the cheap hot stocks to invest in right now. On January 30, Barclays analyst Glen Santangelo raised the price target for Teva Pharmaceuticals to $38 from $35 with an Overweight r... Full story

Yahoo Finance • 26 days ago

The Druckenmiller Connection: Meet the Man Behind Bessent and Warsh

The hedge fund manager is in the unusual position of having mentored two of the most powerful financial leaders in Washington. Continue Reading... Full story

Yahoo Finance • 2 months ago

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline.Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive from stableS&P upgraded Teva to BB+ from BB... Full story

Yahoo Finance • 2 months ago

Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026

Key Points Quarterly-filed Form 13Fs allow investors to track which stocks Wall Street's savviest money managers are buying and selling. Billionaire Stanley Druckenmiller dumped his fund's stakes in AI darlings Nvidia and Palantir -- and... Full story

Yahoo Finance • 2 months ago

Teva Pharmaceutical Industries' (NYSE:TEVA) investors will be pleased with their impressive 228% return over the last three years

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a really great company, you can more than double your money. For instance the Teva Pharmaceutical Industries Limited (NYSE... Full story

Yahoo Finance • 2 months ago

Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S.

[Chemist developing new medicine in laboratory] Luis Alvarez Alvotech (ALVO [https://seekingalpha.com/symbol/ALVO]) and Teva Pharmaceuticals (TEVA [https://seekingalpha.com/symbol/TEVA]) have reached a settlement and license agreement wit... Full story

Yahoo Finance • 2 months ago

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK, Iceland and TEL A... Full story

Yahoo Finance • 2 months ago

Alvotech og Teva ná samningi um að sala AVT06 hliðstæðunnar við Eylea má hefjast í Bandaríkjunum á fjórða ársfjórðungi 2026

Alvotech (NASDAQ: ALVO) og Teva Pharmaceuticals, bandarískt dótturfyrirtæki Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), hafa náð samningi við Regeneron Pharmaceuticals sem veitir Alvotech og Teva heimild til að markaðssetja... Full story

Yahoo Finance • 2 months ago

SPYM, DRKY: Big ETF Inflows

Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the State Street Investment Management, which added 27,150,000 units, or a 2.2% increase week over week. Among... Full story

Yahoo Finance • 2 months ago

Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?

Key Points Shares of Teva -- a generic-drug maker with a history of losses and high leverage -- have rallied strongly. Pfizer and Merck, which make branded drugs, are financially strong and are rebuilding their drug pipelines. 10 stocks w... Full story

Yahoo Finance • 3 months ago

Women’s Healthcare Market Worth USD 46.76 Billion by 2033 Driven by Rising Demand for Reproductive, Preventive, and Digital Health Solutions – SNS Insider

Austin, Texas, Dec. 13, 2025 (GLOBE NEWSWIRE) -- Women's Healthcare Market Size & Growth Analysis: According to SNS Insider, The Women’s Healthcare Market size is estimated at USD 20.20 Billion in 2025 and is projected to reach USD 46.7... Full story

Yahoo Finance • 3 months ago

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026,... Full story